Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 820 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Corgi Named Dolly Didn’t Win At Westminster, But Is A Champion... February 12, 2020 AI-Supported Mammography Screening Shows Favourable Outcomes Compared with Standard Double Reading February 12, 2026 Pembrolizumab Plus Chemoradiotherapy Significantly Improves OS in Patients with Locally Advanced... October 11, 2024 Cancer clinical trials – learning lessons from the COVID-19 pandemic May 19, 2021 Load more HOT NEWS How serendipity sent this oncologist in search of a cure for... FDA Approves Pembrolizumab with Chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical... Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume...
